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INTRODUCTION:
The estrogen receptor (ER), is implicated in the progression of breast cancer 1 . Endocrine therapy using Tamoxifen, a selective estrogen receptor modulator (SERM), has been shown to improve relapse-free and overall survival 2 . More recently, aromatase inhibitors, which deplete peripheral estrogen (E2) synthesis, are shown to substantially improve disease-free survival in postmenopausal women 3 . Furthermore, endocrine therapy also shown to have a positive effect on the treatment of advanced metastatic disease. Despite these positive effects, initial or acquired resistance to endocrine therapies frequently occurs. Accumulating evidence suggests that ERcoregulators play an essential role in hormonal responsiveness and cancer progression [4] [5] [6] . Proline, Glutamic-acid and Leucine-rich Protein 1 (PELP1) is a recently identified novel ER coregulator 7, 8 . Emerging evidence suggests that ER signaling cross talk with growth factors play an important role in hormonal resistance and metastasis. Since multiple signaling pathways in addition to hormone are involved in activating ERs, combination therapies using both endocrine and nonendocrine agents that block different pathways may have better therapeutic effect and may delay development of hormonal resistance. Recent evidence implicates ERcoregulator PELP1/MNAR play an essential role in coupling ER with Src kinases leading hormonal resistance. Since PELP1 is the only ER-coregulator that is shown to couple ER with Src kinase, and because expression of PELP1 and Src are commonly deregulated in breast cancer, we hypothesize that deregulation of PELP1 promotes Src activation and excessive signaling crosstalk with ER, leading to hormonal therapy resistance and metastasis. This proposal is aimed to determine whether PELP1-Src signaling is a rate limiting factor in the development of hormonal independence and metastasis and to test whether blocking of the PELP1-Src pathway in combination with endocrine therapies prevent hormonal therapy resistance and metastasis.
BODY:
The scope of this proposal is to undertake the following three tasks outlined in the approved statement of work: Task 1. To establish the significance of ER-coregulator-Src axis in hormonal resistance and metastasis Task2. To determine the efficacy of targeting of the ER-coregulator-Src axis on hormonal therapy and metastasis
Generation and characterization of model cells cell lines with or without functional ER-PELP1-Src axis.
To establish the significance of ER-PELP1-Src axis, during the first year, we established two additional breast cancer model cells (1) MCF7-GFPPELP1 clone that stably express Src-ShRNA (PELP1-Src-shRNA) and (2) MCF7-HER2 cell stably expressing PELP1-Src-mutant (HER2-PELP1-SrcMT). PELP1-SrcMT contains mutation in the Src-SH3 binding on PELP1 (ProXXPro is mutated to AlaXXAla), thus functions as a dominant negative mutant. Clones were characterized for the functionality of Src down regulation by western analysis (Fig 1,  left panel) . Results showed that Src shRNA down regulates ~80% of endogenous Src expression. We have also characterized expression of PELP1 mutant using Western analysis ( Fig. 1 , right panel). These clones will be used in the second year along with control MCF7-Her2 and MCF7-PELP1 clones to characterize the significance of PELP1-Src axis in therapy resistance and metastasis.
Role of ER-PELP1-Src axis in ER non-genotropic signaling:
To study the in vivo significance of PELP1, we established MCF7 breast cancer model cells that stably expressed PELP1shRNA that specifically down regulate endogenous PELP1. MCF7 cells were transfected with shRNA vector were used as a control. Western blot analysis of total lysates revealed that the PELP1-shRNA clones down regulated PELP1 expression to ~80 % of the level seen in the parental and the vectortransfected clones ( Fig. 2A) . To further establish the role of PELP1 in E2-mediated non-genomic actions, we used EDC (nanoparticles coated with estrogen) that uniquely localize in the membrane/cytoplasm (Fig.  2B) , and preferably activate ERnongenomic signaling 9 . MCF7 cells that expressed vector or PELP1 shRNA were treated with EDC for 2 or 5 min and signaling was analyzed by phosphor-specific antibodies. EDC addition uniquely promoted activation of Src and MAPK pathways. However, knock down of PELP1 by shRNA significantly affected the EDC-mediated increase in Src and MAPK activation (Fig. 2C) . These results suggest that E2-mediated nongenomic actions play a key role 6 in the activation of Src and MAPK and that the functional PELP1 signaling axis is needed for E2-mediated non-genomic signaling.
Significance of PELP1-Src axis on cytoskeleton signaling: Because Src and PI3K play important role in cytoskeleton functions, cell attachment and migration, we asked whether E2-ER nongenomic actions contribute to cytoskeleton reorganization leading to cell migration. MCF7 cells that expressed vector or PELP1 shRNA were treated with either E2 or EDC for 10 min and cytoskeleton changes were analyzed by confocal microscopy. E2 or EDC addition uniquely promoted actin reorganization with filopodia and ruffle formations. However, knock down of PELP1 by shRNA significantly affected actin reorganization by E2 or EDC (Fig.  3 ). These studies demonstrate that ER nongenomic actions have the potential to promote cytoskeleton changes.
Src kinase plays a critical role in PELP1-mediated E2 nongenomic signaling. To establish the significance of Src kinase in PELP1-mediated E2-ER nongenomic signaling, we generated a PELP1 mutant construct (PELP1SrcMT) that contains a mutation in the Src-SH3 binding site on PELP1 (ProXXPro is mutated to AlaXXAla) and a mutation in Src phosphorylation site (Tyr 920 is mutated to Phe, Fig. 4A ). The PELP1SrcMT mutant is unable to interact with Src kinase and thus functions as a dominant negative mutant of PELP1. As expected, PELP1 WT but not the PELP1SrcMT interacted with Src kinase (Fig. 4B) . Transient expression of PELP1SrcMT substantially interfered with E2-mediated activation of Src and MAPK (Fig. 4C) . These results suggest that Src interactions with PELP1 is needed for optimal E2 mediated non genomic actions.
7
Src kinase plays a critical role in PELP1-mediated signaling to cytoskeleton reorganization. To examine whether the significance of Src kinase in PELP1-mediated cytoskeleton reorganization, we transfected MCF7 cells with PELP1 WT and PELP1SrcMT. After 72 hours cells were stimulated with E2 and actin reorganization was measured using confocal microscopy. Expression of PELP1SrcMT substantially effected the E2-mediated cytoskeleton reorganization in a dominant negative fashion (Fig. 5) . These results suggest that PELP1-Src axis play an important role in PELP1-mediated E2 nongenomic actions that contribute to cytoskeletal reorganization.
Effect of Dasatinib on ER-nongenotrophic signaling:
Since Src kinase appears to play a key role in E2 nongenomic signaling, we examined effect of inhibition of Src kinase using dasatinib, a well-established orally available inhibitor of Src family tyrosine kinases 10 . For these studies, we used MCF7 control cells or MCF7-PELP1 model cells that overexpress PELP1 and exhibit increased E2-ER nongenomic signaling. Pharmacological inhibition of Src kinase using dasatinib abolished the E2-mediated activation of AKT and MAPK pathways both in MCF7 as well as in PELP1-overexpressing MCF7 cells (Fig. 6 ). These results suggest that pharmacological inhibitor dasatinib can be used to block E2-driven PELP1-mediated nongenomic signaling.
PELP1 is needed for optimal cell migration promoted by E2 nongenomic actions. Because activation of PELP1-src axis by E2 nongenomic actions played a role in cytoskeleton reorganization, we examined whether E2-mediated nongenomic actions contribute to cell migration. In Boyden chamber assays, parental MCF7 cells showed low motility, and EDC further increased the migratory potential of those cells. The knockdown of PELP1 expression by siRNA substantially reduced EDC-mediated cell motility (Fig. 7) . These data suggest that E2-PELP1 signaling potentially play a role in cell migration. 
CONCLUSIONS:
In the first year of this study, we have generated model cells that have defects in PELP1-Src signaling axis. Using these models, we demonstrated that ER-nongenotropic actions play an important role in cell motility, establishing for the first time that endogenous PELP1 has as a critical role in activating signaling events that lead to cell motility/invasion via ER-Src-PELP1 pathway. Our results using estrogen dendrimers (EDC) demonstrates that ER nongenomic signaling has potential to promote cytoskeletal changes, leading to increased cell migration. Our data suggest that PELP1 and Src kinase play an essential role in the activation of ER nongenomic signaling leading to cytoskeleton reorganization and migration. Since breast tumors overexpress Src kinase, deregulation of PELP1 seen in breast tumors can contribute to activation of Src kinase, leading to the progression to metastasis. Pharmacological inhibition of Src kinase using dasatinib significantly inhibited E2-mediated nongenomic actions. These results suggest that the ER-Src-PELP1 axis is a novel target for preventing the emergence of metastatic cells and that
Dasatinib may have therapeutic utility in blocking ER-positive metastases. Our ongoing studies in the second year will address the role of PELP1 in breast cancer cell migration in vivo, therapeutic potential of Dasatinib in sensitizing therapy resistant cells and to lock local estrogen synthesis.
Estrogen receptor (ER) is implicated in breast cancer progression and the majority of the human breast cancers start out as hormone-dependent. A large portion of metastases retain their ER when the primary tumors are ER+ve. Several recent studies detected the presence of ER, ER-coregulator Proline Glutamic acid Leucine rich Protein 1 (PELP1), and aromatase in metastatic breast tumors. Even through substantial information is available on the mechanism of ER-ve metastasis, the role of ER signaling in ER +ve breast metastasis is an understudied area. Emerging evidence suggests that in addition to wellstudied nuclear functions, ER also participates in non-genomic (cytoplasmic and membrane-mediated) signaling. In this study we examined whether ER non-genomic signaling play a role in ER+ve metastasis. To dissect the mechanism of ER non-genomic signaling on cell migration and metastasis, we used ligands (estrogen, estrogen-dendrimers), shRNA (ER, PELP1, Src), dominant active or negative constructs of PELP1 and Src and ER positive breast cancer cells (MCF7, ZR75) that over express GFP vector or GFP-PELP1. Our studies revealed that PELP1 and Src kinase play an essential role in the activation of ER non-genomic signaling leading to cell migration. Blockage of ER-PELP1-Src axis using dominant negative mutants significantly affected ER non-genomic signaling. PELP1 mutant that cannot bind Src kinase functioned as dominant negative and substantially affected ER non-genomic signaling leading to defects in cytoskeleton. Using dominant negative and active constructs of PELP1 and Src, we have identified that E2 non-genomic signaling promotes cytoskeleton reorganization via ER-PELP1-Src pathway. Utilizing Boyden chamber assays, we have demonstrated that deregulation of PELP1 contribute to increased cell migratory function via excessive activation of Src kinase and by promotion of local estrogen synthesis. Nude mice injected (tail route) with ZR75-GFP control cells showed 0-1 metastatic nodules while ZR75-PELP1 cells showed increased propensity to metastasize with 8-12 nodules in lungs and 6-8 nodules in liver. Nude mice injected (cardiac route), ZR75-PELP1GFP, but not control GFP cells, showed metastases to bone. [6] . Coregulators appear to have the potential to sense the physiological signals [7] and activate appropriate set of genes, thus have potential to function as master regulators, and their deregulation is likely to provide cancer cells an advantage in survival, growth and metastasis [8;9] . A commonly emerging theme is that marked alteration in the levels and functions of coregulators occurs during the progression of tumorigenesis [10] .
Although much is known about the molecular basis of interaction between ER and coregulators, very little is known about the physiological role of coregulators in the initiation and progression of cancer.
Regulation of aromatase in Breast
Aromatase (Cyp19), a key enzyme involved in E2 synthesis [11] , is expressed in breast tumors and locally produced E2 might act in a paracrine or autocrine fashion [12] . Breast tumors from postmenopausal women are shown to contain higher amounts of E2 than would be predicted from levels circulating in plasma [13] . Expression of the aromatase gene is under the control of several distinct and tissue-specific promoters; however, the coding region of aromatase transcripts and the resulting protein is identical [14] . In disease free breast, aromatase expression is directed via distal 1.4 promoter, while aromatase expression is shown to be activated via PII and 1.3 in adipose tissue and epithelial cells in breast bearing tumor [15] [16] [17] .
Recently, aromatase inhibitors that inhibit peripheral E2 synthesis are shown to be more effective in enhancing the survival of postmenopausal women with ER+ve breast cancer [18] . Even though these new treatments appear successful, emerging data suggest that tumors evade this treatment by developing "adaptive hypersensitivity" manifested as hormone-independent tumorigenesis through increased non-genomic signaling and growth factor signaling crosstalk [19] [20] [21] . Recent studies also demonstrated that HER2 status plays an important role in tumorinduced aromatase activity via the COX-2 pathway [22] . Further, HER2 overexpression can also promote ligand-independent recruitment of coactivator complexes to E2-responsive promoters, and thus may play a role in the development of letrozole resistance [21] . Accumulating evidence also suggest that a variety of different factors may regulate expression and activity of aromatase under pathological conditions and local production of estrogen may enhance tumor growth and may also interfere with hormone therapy [23] . The molecular mechanism by which breast tumors enhance local aromatase expression and whether epigenetic changes play a role in activation of aromatase in tumors remain unknown and is an active area of research investigation.
PELP1, a novel ER coregulator
Proline, glutamic acid, leucine rich protein 1 (PELP1), also called as a modulator of nongenomic actions of estrogen receptor (MNAR) is a novel ER coregulator [24] [25]. PELP1
contains several motifs and domains that are commonly present in many transcriptional coactivators, including 10 nuclear receptor (NR)-interacting boxes (LXXLL motifs), a zinc finger motif, a glutamic acid-rich domain, and 2 proline-rich domains ( Figure 1 ) [24;25] . A unique feature of PELP1 is the presence of an unusual stretch of 70 acidic amino acids in the C-terminus that functions as a histone-binding region [26;27] . PELP1 is localized both in the nuclear and cytoplasmic compartments. In the nuclear compartment PELP1 interacts with histones and histone modifying enzymes, suggesting that PELP1 has some function in these complexes [28;29] and thus plays a role in chromatin remodeling for ligand-bound ERs [27] . Emerging evidence also indicates that PELP1 plays a key role in extra nuclear actions of nuclear receptors and thus represents a unique ER coregulator that participates in both genomic and non genomic actions of ER. PELP1 modulates the interaction of estrogen receptor with Src, stimulates Src enzymatic activity and thus enhances MAPK pathway activation [25] . PELP1 is also shown to directly interact with the p85 subunit of PI3K and enhances PI3K activity, leading to activation of the PKB/AKT pathway [30] . Mechanistic studies showed that PELP1 interacts with the SH3 domain of c-Src via its N-terminal PXXP motif, and ER interacts with the SH2 domain of Src at phosphotyrosine 537; the PELP1-ER interaction further stabilizes this trimeric complex, leading to activation of Src kinase. Activated Src kinase then phosphorylates PELP1, which in turn acts as a docking site for PI3K leading to activation of PKB/AKT pathway [31] . PELP1 interacts with and modulates functions of several nuclear receptors and transcriptional activators including AR, ERR, GR, PR, RXR, FHL2 and STAT3 [28] . PELP1 promotes E2-mediated cell proliferation by sensitizing cells to G1>S progression via its interactions with the pRb pathway [32] . PELP1 is shown to be phosphorylated by several kinases including PKA, HER2, Src, CDKs and its phosphorylation is modulated by estrogen and growth factors [28] . Collectively, these findings suggest that PELP1 serves as a scaffolding protein that couples various signaling complexes with estrogen receptor and participates in genomic and non-genomic functions (Fig. 1) .
PELP1 expression in hormonal cancers
Emerging studies suggest that PELP1 is a proto-oncogene and its expression is deregulated in hormone dependent cancers including cancers of breast [24;33] , endometrium [34] and ovary [35] . Although PELP1 is predominantly localized in the nuclei of hormonally responsive tissue cells, in a subset of tumors it localizes in the cytoplasm alone [30] . Altered localization of PELP1 appears to contribute to tamoxifen resistance via excessive activation of Src/AKT pathways leading to follow-up modifications of ER [30] . Such modifications of the ER pathway may lead to the activation of ER target genes in a ligand-independent manner. Thus, deregulation of PELP1 expression has the potential to contribute to hormonal therapy resistance seen in patients with hormone-dependent neoplasm by excessively activating extra nuclear signaling pathways.
PELP1 deregulation promotes local induction of aromatase.
Recent studies from our laboratory showed that PELP1 functions as a potential protooncogene [36] . In this study, we found that breast cancer cells stably overexpressing PELP1
showed a rapid tumor growth in xenograft studies compared to control vector transfectants and tumor growth in PELP1 clones occurred in the absence of external estrogen supplementation.
These findings raised a hypothesis that PELP1 deregulation modulates local aromatase to produce local estrogen thus promoting tumor growth without exogenous E2 supplementation.
Immunohistochemistry (IHC) analysis of the PELP1 induced xenograft tumors using aromatase specific antibody showed that PELP1 driven tumors have increased aromatase expression compared to control E2 induced MCF-7 tumors (Fig. 2A) . Results from studies using exon specific primers showed that MCF7 clones that overexpress PELP1 showed increased levels of exon I.3/II transcripts compared to MCF7 parental clones. In reporter gene assays utilizing Aro 1.3/II-luc, MCF7-PELP1 cells showed a 5-fold increase in the reporter gene activity (Fig. 2B ).
Western blot analysis showed that MCF7-PELP1 clones have increased levels of aromatase compared to the aromatase levels in the control MCF7 cells (Fig.2B ). PELP1 expressing MCF7 cells also showed increased aromatase activity suggesting the functionality of induced aromatase (Fig.2C) . Collectively, these results suggest that PELP1 deregulation has potential to regulate the aromatase gene expression via the I.3/PII promoter and such deregulation could contribute to local E2 synthesis.
Role of PELP1 in growth factor regulation of Aromatase
Deregulation of HER2 oncogene expression/signaling has emerged as the most significant factor in the development of hormone resistance. ER expression occurs in ~50%
HER2-positive breast cancers and cross-talk between the ER and HER2 pathways promotes endocrine therapy resistance [37] . ER-coregulators are targeted by excessive ER-HER2 crosstalk leading to hormone resistance in a subset of breast tumors [38] . Recent studies also demonstrated that HER2 status plays an important role in tumor-induced aromatase activity via the COX-2 pathway [22] . Earlier studies showed that PELP1 interacts with HER2 and EGFR signaling components, and HER signaling promotes tyrosine phosphorylation of PELP1 [34;39] . In our studies, we found that growth factor signaling enhances PELP1 regulation of the aromatase promoter and resulted in increased aromatase activity [40] . We also found that PELP1 overexpression, or growth factor signaling enhances PELP1 recruitment to the silencer regions of the promoter I.3/II, suggesting that PELP1 could be one of those factors that promote aromatase expression via activation of the 1.3/II promoters under conditions of growth factor deregulation (Fig. 3) .
Expression of PELP1 and aromatase in breast tumors.
Since PELP1 deregulation promotes aromatase expression in breast epithelial cells, we 
PELP1 regulation of aromatase expression in vivo
To test whether PELP1 deregulation in vivo has potential to regulate aromatase expression, our laboratory recently developed a transgenic mice (Tg) model. (Fig. 2E) . These results thus provide evidence for in vivo potential of PELP1 deregulation in enhancing local E2 synthesis.
PELP1 and aromatase expression in endometriosis
Several lines of evidence demonstrate local estradiol (E2) production in endometriosis lesions [41;42] . Aberrant expression of steroidogenic acute regulatory protein (StAR) and aromatase in endometriotic tissue is shown to result in up-regulation of estrogen production [43] .
Evolving evidence indicate that in cancers of breast, endometrium and ovary, aromatase expression is primarily regulated by increased activity of the proximally located promoter AroI.3/II region [44] . To examine whether PELP1 has potential to regulate aromatase expression in endometrial cells, we performed reporter gene activation assays. Cotransfection of GFP-
PELP1 but not GFP vector in human endometrial stromal cells (HESC) showed increased
aromatase reporter activity and expression (Fig. 2F) . Since PELP1 expression is deregulated in some ER driven pathological situations, we examined the expression status of PELP1 and aromatase in a small number (n=5) of eutopic and ectopic endometrium. Results showed increased staining intensity of PELP1 in ectopic endometrium compared to eutopic endometrium (Fig. 2G ). In addition, ectopic endometrium also showed increase in aromatase staining.
Collectively, these results suggest a possibility that PELP1 has potential to modulate aromatase expression in endometrial cells and it expression may be deregulated in endometriosis.
PELP1 regulation of aromatase in ovarian cancer cells
Our recently completed study using ovarian cancer tissue arrays suggested that PELP1 deregulation occurs in different types of ovarian cancer [35] . Results suggested that deregulation of PELP1 occurs in all subtypes of ovarian cancer (including serous, endometerioid, clear cell carcinoma, and mucinous tumors) and 60 % of the tumors have 2-3 fold increase in PELP1 staining intensity (Fig. 2H ). Since emerging evidence implicates that local estrogen synthesis also play a role in ovarian tumorigenesis, we have examined whether PELP1 regulates aromatase activation in ovarian cancer cells using Aro1.3/II promoter that is shown to be active in ovarian cells. In reporter gene assays, PELP1 enhanced the activation of Aro 1.3/II promoter activity in BG1 cells in a dose dependent manner (Fig. 2I ). Western analysis of PELP1 overexpressing BG1
clones showed that PELP1 overexpression increases aromatase expression in ovarian cancer cells (Fig. 2J) . These results suggest that PELP1 deregulation also has potential to promote local E2 synthesis in ovarian cancer cells.
Role of PELP1 mediated non-genomic actions in aromatase induction
PELP1 is a unique regulator of nuclear receptor that participates in genomic as well as in non-genomic actions [28] . To examine whether PELP1 mediated non-genomic signaling pathways are involved in PELP1-mediated induction of aromatase expression, we pretreated MCF7-PELP1 cells with various signaling inhibitors that block specific pathways: PD98059, mitogen-activated protein/extracellular signal-regulated kinase inhibitor; PP2, the Src family tyrosine kinase inhibitor; LY-294002, the PI3K inhibitor; SB203580, and the p38MAPK inhibitor. Results from these assays showed that PELP1-induced aromatase promoter activity can be abolished by pretreatment with c-Src or PI3K pathway inhibitors while pretreatment of MAPK pathway inhibitors had no effect on PELP1-induced aromatase expression. These results suggest that functional c-Src and PI3K pathways are required for PELP1-mediated induction of aromatase (Fig. 3) . Similarly, HER2 regulation of PELP1-mediated activation of aromatase was also abolished by pretreatment of MCF7-HER2 cells with the Src inhibitor PP2. Collectively, the findings from this published study suggest that c-Src signaling plays a vital role in PELP1 mediated induction of aromatase [40] .
Role of PELP1 genomic functions in aromatase induction
PELP1 is predominantly nuclear in localization and earlier studies showed that PELP1 is recruited to several nuclear receptor target genes and play a role in chromatin modifications.
Using various deletion constructs of aromatase promoter reporter gene and by ChIP analysis of aromatase promoter, we found that 269 base region located in the -231/+38 Aro P1.3/II promoter is required for PELP1 regulation of aromatase (Fig. 3) . In addition, ChIP analysis showed that PELP1 is specifically recruited to the -231/+38 region. Further analysis revealed that HER2 signaling also required Aro 1.3/II -231/+38 region for PELP1-mediated activation of aromatase.
Earlier studies showed that this region possess binding regions for ERRα, BRCA1 and a transcriptional silencer element (S1) [45] . Immunoprecipitation analysis revealed that PELP1
interacts with ERR but not with BRCA1. Using reporter gene assays, ERR specific siRNA and ERR antagonist, we found that PELP1 promotes activation of Aro1.3/II promoter via interactions with the ERRα [40] . Earlier studies found that ERR up-regulates aromatase expression via the I.3/II promoters [46] . Since PELP1 does not have a DNA binding domain, it is possible that ERRα serves as a docking site for PELP1 recruitment and PELP1 ability to interacts with histones and histone modifying enzymes, may play a role in chromatin remodeling at aromatase promoter (Fig. 3) 
Significance of PELP1 in epigenetic modifications of aromatase promoter
Emerging evidence suggest that histone methylation, an epigenetic phenomena, could play a vital role in many neoplastic processes by silencing or activation of genes [47] . However, unlike genetic alterations, epigenetic changes are reversible. Recent studies showed that demethylase LSD1 can demethylate H3-K4 and H3-K9, recruits to a significant fraction of ER target genes and is shown to be required to demethylate proximal histones to enable ERmediated transcription [48] . Evolving studies in our laboratory suggest that PELP1 interacts with LSD1 and also recognizes methyl modified histones [49] [28] . Because PELP1 is recruited to aromatase promoter and interacts with histone demethylase, it is possible that PELP1 modulate H3 methyl modifications at the aromatase promoter. ChIP analysis revealed that MCF7 cells that do not express aromatase showed increased H3K9 methylation (a marker of repression),
while MCF7-PELP1 model cells (that overexpress PELP1) that exhibit local E2 synthesis showed decreased histone H3K9 with a concomitant increase in H3K4 methylation (a marker of activation) at the aromatase promoter. Interestingly, other model cells that exhibit increased local E2 synthesis (MCF7-HER2, SKBR3) also showed increased H3K4 methylation at aromatase promoter (Fig. 4A) . These results suggest that epigenetic modification may play a role in the local aromatase expression and PELP1 deregulation could play a role in modulating histone methylation at the aromatase promoter region.
Targeting local estrogen synthesis by blocking PELP1-LSD1 axis
Pargyline is a selective monoamine oxidase inhibitor that blocks LSD1 activity [50] and is approved by FDA for treatment of moderate to severe hypertension. Pargyline is commercially available from many sources and the safety and efficacy of this drug is well established. Since PELP1 expression is deregulated in hormonal dependent tumors, and because PELP1 interacts with LSD1 and promotes local E2 synthesis, inhibition of PELP1-LSD1 axis by inhibitor
Pargyline will probably affect growth advantage seen in the PELP1 overexpressing cells by reducing local E2 synthesis. To test this, MCF7-PELP1 cells that over express PELP1, MCF7-HER2 cells that overexpress oncogene HER2, were treated with or without Pargyline (3 mM) for 72 h and the cell viability was determined by Cell titer-glo ATP assay (Promega). Pargyline substantially inhibited viability in both model cells (Fig. 4B, C) . These results suggest that PELP1 mediated epigenetic modifications may play a role in local E2 synthesis and blocking PELP1-LSD1 axis will have therapeutic utility (Fig. 4D ). 
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